UNSPSC 51332205: Carpipramine dihydrochloride monohydrate

This classification denotes an antidepressant agent with the molecular formula C28H38N4O.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53X71X3I1W, chemically known as 1'-(3-(10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)-(1,4'-bipiperidine)-4'-carboxamide dihydrochloride monohydrate, but more generally known as carpipramine dihydrochloride monohydrate, which bears US NIH Compound Identifier 23476.

European Medicines Agency schedules carpipramine dihydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06142MIG. Most nations, for tariff purposes, schedule carpipramine dihydrochloride monohydrate under HS 29333999. SMILES: C1CCC2C(C1)CCC3CCCCC3N2CCCN4CCC(CC4)(C(=O)N)N5CCCCC5.O.CL.CL.

UNSPSC 51332205 Carpipramine dihydrochloride monohydrate (Commodity) represents a narrow pharmaceutical active ingredient that shows minimal alignment with recent state and local procurement activity. The code nominally describes a specific tricyclic antidepressant compound, but the recent opportunities tagged under this code actually procure finished pharmaceutical products, OTC items, and drug-management systems rather than raw chemical ingredients or bulk active pharmaceutical ingredients (APIs). State and local governments do not regularly purchase individual chemical entities in this format; instead, they acquire finished dosage forms (tablets, injections, solutions) through cooperative purchasing vehicles, multi-jurisdictional pharmaceutical consortia, and county health programs. The mismatch between the code's specificity and the breadth of actual procurement activity suggests either tagging error in source systems or that this code functions as a placeholder within broader pharmaceutical family classifications.

The three recent opportunities identified—Seminole County, Florida's IFB for naloxone and drug deactivation systems (due Jul 26, 2023); Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (due Apr 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (due Mar 26, 2026)—span states including Florida, Texas, and Minnesota with interstate cooperative mechanisms. None of these solicitations directly source carpipramine or its variants; the code appears to capture pharmaceutical procurement broadly while the actual commodities range from naloxone kits to generic generics distributed through established wholesalers. Activity concentrates in state health departments and cooperative purchasing alliances rather than individual municipalities or school districts. Given the limited relevance of this specific API code to material recent procurement and the absence of direct opportunities for carpipramine itself, pursuing this code category presents minimal near-term opportunity unless your firm manufactures or distributes finished pharmaceutical products through state health systems or cooperative purchasing networks.